Mr. Lanfear, InteKrin’s Founder and President, became Chairman of the Board in 2010. Under Mr. Lanfear’s five year leadership as President and CEO, the company was taken from inception through a successful End-Of-Phase-2 meeting with the FDA and into Phase 3 with a major therapeutic area lead product of high market potential.

Denny is a thirteen year veteran of Amgen, Inc. where he was a Corporate Officer and Vice-President with broad operational, product development and marketing responsibility. His tenure began in 1986 as a founding member of the Process Development Department. Under his ten-year leadership this group became the preeminent PD organization in BioPharma and a key strategic advantage for the company, as it remains today. As Vice President Process Development and Operations Systems, he directed the business process integration of over twenty-five hundred Operations and Quality staff world-wide.

While at Amgen he also had senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. He reviewed and wrote sections of more that 20 INDs and several BLAs. He managed several corporate partner relationships including that with SKB from 1986 to 1990. He also managed and had direct budgetary responsibility for the $135M development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 he was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug.

Prior to joining Amgen, Denny held positions of increasing responsibility at Baxter International. Denny was also the founder and former CEO of Saronyx, Inc., a drug development software services company. He is also an active life science investor through his firm Lanfear Capital Advisers, which invests in pharmaceutical and medical device companies. He is an investor and former Director of Anthera Pharmaceuticals. He is a Director of Insmed Therapeutics. Lanfear Capital is also Limited Partner in select venture funds.

Denny earned degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his MBA from the Anderson School at UCLA.

Mr. Brand brings more than 30 years of global pharmaceutical experience in product development, acquisitions, marketing and operational management with GlaxoSmithKline, its predecessor companies, and most recently as President and CEO of Cardiokine.

Mr. Brand joined GSK International from the Canadian operation in 1983 in the post of Vice President, Cardiovascular/Gastrointestinal Marketing. Over the next 7 years, he held VP positions in marketing, business development, and regional operations in Asia, Europe and Latin America.

In 1990, Mr. Brand joined the GSK US organization as Business Unit Head for Gastrointestinal and Central Nervous System Products, where he led the launch activities for Paxil and Kytril. In 1994, as Vice President of New Product Planning, he was responsible for the pre-launch commercial development plans for Coreg, Hycamptin, Requip and numerous in-licensing, co-promotion, co-development partnerships. From 1997 through 2003, Mr Brand headed up the anti-infective, metabolic and cardiovascular business units that launched Requip, Avandia and Avandia extensions, and development of Augmentin ES/XR.

From 2004 to September 2007, Mr. Brand served as President and CEO of Cardiokine, a specialty pharmaceutical company developing lixivaptan. Over this period, Mr. Brand built a first class management and development team, successfully closed a $50 million Series B financing and completed a global lixivaptan co-development, co-marketing agreement with Biogen Idec.

Mr. Brand holds a Bachelor of Commerce degree from Concordia University in Montreal, Canada.

Dr. Crooke is a co-founder and partner of Helix Ventures, a healthcare-focused venture capital firm. From April 2000 to July 2009, Dr. Crooke led the healthcare investment effort at Asset Management Company (AMC), a Silicon Valley venture capital firm. Prior to joining AMC, he worked on biotechnology and healthcare service investments with Dillon Read Venture Capital and later its successor firm, Ticonderoga Capital. He has also worked as a management consultant focused on healthcare at the international consulting firm of Booz, Allen & Hamilton and prior to that as a product manager at Molecular Devices Corporation, a venture-backed bioanalytical company. In 1983 he received his medical degree from the University of Western Australia and then worked at major teaching hospitals in his home of Perth until 1986. He then attended the Stanford University Graduate School of Business, where he earned his MBA in 1988. He is a director of several private companies.

Jim Healy, M.D., Ph.D., General Partner, joined Sofinnova in the spring of 2000. In the words of one entrepreneur, Jim has an "unparalleled work ethic." Prior to joining Sofinnova, he had experience with both pharmaceutical products and research platforms. In the pharmaceutical industry he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. He also has experience with research tools and platforms through his involvement at the Human Genome Center at Lawrence Berkeley Labs.

Jim has authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling. Jim earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received the Departmental Citation. Jim received his M.D. from Stanford School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation.

Details Coming Soon

Harold E. "Barry" Selick, Ph.D. has been Chief Executive Officer of Threshold Pharmaceuticals since May 2003. Since June 2002, Dr. Selick has been a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc.. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection.

Dr. Selick also serves on the Board of Directors of DiObex, Inc. and Catalyst Biosciences. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.